• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HilleVax Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/10/24 4:05:10 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    8-K
    0001888012false--12-3100018880122024-06-062024-06-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 06, 2024

     

     

    HILLEVAX, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41365

    85-0545060

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    321 Harrison Avenue

     

    Boston, Massachusetts

     

    02118

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 617 213-5054

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    HLVX

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

     

    Item 3.03. Material Modification to Rights of Security Holders.

    To the extent required by Item 3.03 of Form 8-K, the information set forth under Item 5.03 of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    HilleVax, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on June 6, 2024. At the Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to eliminate the personal liability of the Company’s officers for monetary damages for any breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by the Delaware General Corporation Law (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on June 7, 2024 (the Certificate of Amendment). The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

    Proposal No. 1 - Election of Class II Directors

    At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class II directors for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

     

     

     

     

     

     

     

     

     

     

     

     

    Directors

    Votes For

    Withheld

    Broker Non-Votes

    Gary Dubin, M.D.

    32,942,834

     

    416,691

     

    5,548,516

     

    Patrick Heron

    32,799,922

     

    718,537

     

    5,389,582

     

    Jaime Sepulveda, M.D., D.Sc., M.P.H

     

    32,833,456

     

     

     

    685,003

     

     

     

    5,389,582

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm

    At the Annual Meeting, the Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2024:

     

     

     

     

     

    Votes For

    Votes Against

    Abstentions

    38,876,904

    1,368

    29,769

    Proposal No. 3 - Amendment to our Amended and Restated Certificate of Incorporation

    At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions to permit exculpation of certain officers.

     

     

     

     

     

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    31,549,305

    1,976,241

    502

    5,381,993

     

     


     

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

     

     

    Exhibit
    No.

    Description

     

     

    3.1

    Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated June 7, 2024

     

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    HilleVax, Inc.

     

     

     

     

    Date:

    June 10, 2024

    By:

    /s/ Paul S. Bavier

     

     

     

    Name: Paul S. Bavier
    Title: General Counsel and Chief Administrative Officer

     

     


    Get the next $HLVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HilleVax downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

    7/9/24 9:48:14 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by Stifel with a new price target

    Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

    7/9/24 7:46:22 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

    7/9/24 7:46:01 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    SEC Filings

    View All

    SEC Form 15-12G filed by HilleVax Inc.

    15-12G - HilleVax, Inc. (0001888012) (Filer)

    9/29/25 6:10:34 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by HilleVax Inc.

    EFFECT - HilleVax, Inc. (0001888012) (Filer)

    9/23/25 12:15:10 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by HilleVax Inc.

    EFFECT - HilleVax, Inc. (0001888012) (Filer)

    9/23/25 12:15:06 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

    EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ:HLVX) ("HilleVax") common stock for a price per share of $1.95 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price"). The tender offer and related withdrawal rights expired one minute after 11:59

    9/17/25 9:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports Second Quarter 2025 Financial Results

    BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second Quarter Financial Results As of June 30, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively. Research and development expenses were $3.3 million, compared to $52.6 million for the six months ended June 30, 2025 and 2024. The decrease was primarily due to lower clinical development costs. General and administrative expenses were $11.3 million,

    8/6/25 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Takeda Pharmaceutical Co Ltd

    4 - HilleVax, Inc. (0001888012) (Issuer)

    9/19/25 7:23:13 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Large owner Frazier Life Sciences X, L.P.

    4 - HilleVax, Inc. (0001888012) (Issuer)

    9/17/25 5:20:18 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Cocero Nanette closing all direct ownership in the company (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    9/17/25 4:30:15 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/8/24 4:22:13 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/1/24 4:08:42 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    View All

    Frazier Life Sciences Appoints Aditya Kohli to Partner

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

    4/17/25 8:00:00 AM ET
    $HLVX
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

    Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

    5/9/24 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

    BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

    1/18/24 7:00:00 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:36:33 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:00:08 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by HilleVax Inc.

    SC 13G - HilleVax, Inc. (0001888012) (Subject)

    7/22/24 9:02:05 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Financials

    Live finance-specific insights

    View All

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

    BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

    9/1/22 5:18:14 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care